Her2 Amplified Breast Cancer - Genetic Mutations

Relevant Publications

METTL18 functions as a Phenotypic Regulator in Src-Dependent Oncogenic Responses of HER2-Negative Breast Cancer.

Issue Release: 2024

The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.

Issue Release: 2024

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.

Issue Release: 2024

Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.

Issue Release: 2024

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J.

Issue Release: 2024

Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.

Issue Release: 2024

Partial response to trastuzumab deruxtecan (DS8201) following progression in HER2-amplified breast cancer with pulmonary metastases managed with disitamab vedotin (RC48): a comprehensive case report and literature review.

Issue Release: 2024

Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer.

Issue Release: 2024

Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study.

Issue Release: 2024

Association of mammographic and sonographic findings with prognostic molecular factors and hormone receptor expression in malignant breast lesions.

Issue Release: 2024

Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival.

Issue Release: 2024

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.

Issue Release: 2024

Kataegis in clinical and molecular subgroups of primary breast cancer.

Issue Release: 2024

Overcoming retinoic acid resistance in HER2-enriched breast cancers: role of MYC.

Issue Release: 2024

Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.

Issue Release: 2024

Mutational landscape of HSP family on human breast cancer.

Issue Release: 2024

Ferroptosis - a potential feature underlying neratinib-induced colonic epithelial injury.

Issue Release: 2024

Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study.

Issue Release: 2024

Baseline [F]FDG PET/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy.

Issue Release: 2024

Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice.

Issue Release: 2024

What is Immunotherapy?

Why are Non-Coding Regions Important?

How is Sickle Cell Anemia Inherited?

How Do Mutations Occur?

How is Sickle Cell Trait Diagnosed?

What is Genetic Coding?

What is Mutagenesis?

How Does the Delta F508 Mutation Affect the CFTR Protein?

How Are Genetic Diseases Diagnosed?

How Does the Body Repair UV-Induced DNA Damage?

Her2 Amplified Breast Cancer - Genetic Mutations

Relevant Publications

Partnered Content Networks

Relevant Topics